WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in a fireside chat at 10:00 a.m. E.T. on Tuesday, November 12, 2024 at Guggenheim's Inaugural Healthcare Innovation Conference in Boston, MA. A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following the event. About Q32 Bio Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting potent reg

WALTHAM, Mass., Aug. 29, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in three upcoming investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare ConferenceDate: Thursday, September 5, 2024Location: New York, NY 2024 Cantor Fitzgerald Global Healthcare ConferenceDate: Tuesday, September 17, 2024Presentation Time: 3:40 p.m. E.T.Location: New York, NY Stifel 2024 Virtual Immunology and Inflammation SummitDate: Wednesday, September 18, 2024Presentation Time: 11:30 a.m. E.T.Location: Virtual A webc

U.S. stocks were lower, with the Dow Jones index falling around 350 points on Wednesday. Shares of AT&T Inc. (NYSE:T) rose during Wednesday's session following second-quarter earnings. AT&T reported fiscal second-quarter 2024 operating revenues of $29.8 billion, down 0.4% year over year and missing the analyst consensus estimate of $29.9 billion. Adjusted EPS of 57 cents is in line with the analyst consensus estimate, according to data from Benzinga Pro. AT&T shares gained 3.1% to $18.78 on Wednesday. Here are some other big stocks recording gains in today’s session. PROG Holdings, Inc. (NYSE:PRG) shares jumped 20.4% to $41.71 after the company reported better-than-expected s

Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that the company is joining the broad-market Russell 3000® Index at the conclusion of the 2024 Russell Indexes annual reconstitution, effective upon the U.S. market opening today, July 1, 2024.

BBY: 4% | UBS Upgrades Best Buy Co to Buy, Raises Price Target to $106 ZYME: 13% | Zymeworks shares are trading higher after the FDA cleared the company's Investigational New Drug application for Zw171 for mesothelin-expressing cancers, with the company expecting to initiate clinical development during 2024. QTTB: 9% | Q32 Bio shares are trading higher after Guggenheim initiated coverage with a Buy rating and a $100 price target.

Guggenheim analyst Yatin Suneja initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Buy rating and announces Price Target of $100.

Leerink Partners analyst Thomas Smith initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Outperform rating and announces Price Target of $54.

SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)

SC 13G - Q32 Bio Inc. (0001661998) (Subject)

SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)

WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in a fireside chat at 10:00 a.m. E.T. on Tuesday, November 12, 2024 at Guggenheim's Inaugural Healthcare Innovation Conference in Boston, MA. A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following the event. About Q32 Bio Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting potent reg

WALTHAM, Mass., Aug. 29, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in three upcoming investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare ConferenceDate: Thursday, September 5, 2024Location: New York, NY 2024 Cantor Fitzgerald Global Healthcare ConferenceDate: Tuesday, September 17, 2024Presentation Time: 3:40 p.m. E.T.Location: New York, NY Stifel 2024 Virtual Immunology and Inflammation SummitDate: Wednesday, September 18, 2024Presentation Time: 11:30 a.m. E.T.Location: Virtual A webc

4 - Q32 Bio Inc. (0001661998) (Issuer)

4 - Q32 Bio Inc. (0001661998) (Issuer)

4 - Q32 Bio Inc. (0001661998) (Issuer)

4 - Q32 Bio Inc. (0001661998) (Issuer)

4 - Q32 Bio Inc. (0001661998) (Issuer)

4 - Q32 Bio Inc. (0001661998) (Issuer)

424B3 - Q32 Bio Inc. (0001661998) (Filer)

10-Q - Q32 Bio Inc. (0001661998) (Filer)

8-K - Q32 Bio Inc. (0001661998) (Filer)

424B3 - Q32 Bio Inc. (0001661998) (Filer)

10-Q - Q32 Bio Inc. (0001661998) (Filer)

8-K - Q32 Bio Inc. (0001661998) (Filer)

424B3 - Q32 Bio Inc. (0001661998) (Filer)

8-K - Q32 Bio Inc. (0001661998) (Filer)

S-8 - Q32 Bio Inc. (0001661998) (Filer)

Raymond James initiated coverage of Q32 Bio with a rating of Strong Buy and set a new price target of $90.00

Wells Fargo initiated coverage of Q32 Bio with a rating of Overweight and set a new price target of $95.00

Guggenheim initiated coverage of Q32 Bio with a rating of Buy and set a new price target of $100.00

Leerink Partners initiated coverage of Q32 Bio with a rating of Outperform and set a new price target of $54.00